Skip to content

Effect of a training regime featuring the I-Travle system on arm function and skill performance in chronic stroke patients: a single arm trial.

Effect of a training regime featuring the I-Travle system on arm function and skill performance in chronic stroke patients: a single arm trial. - I-TRAVLE study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38961
Enrollment
10
Registered
2013-09-11
Start date
2013-12-16
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstruction of a bloodvessel or bleeding in the brain stroke

Interventions

Haptic feedback of the I-TRAVLE robot either supports or challenges the patient to perform movements of the arm, thereby training motor control and co-ordination of the affected arm. Also strength a

Sponsors

Adelante Kenniscentrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: o Age >

Exclusion criteria

Exclusion criteria: o Severe spasticity of the arm, i.e. Modified Ashworth Scale (MAS) score for the elbow and wrist flexors: each * 3; o Severe visual impairment and/or severe cognitive impairment which may interfere with the execution of the arm-hand tasks or the measurements; o Severe neglect in the near extra personal space, established by the letter cancellation test and Bell*s test (quantitative evaluation) with a minimum omission score of 15%; o Broca aphasia, Wernicke aphasia, global aphasia: as determined by the Akense Afasie Test (AAT); o Severe apraxia as measured by the apraxia test of van Heugten; o no informed consent.

Design outcomes

Primary

MeasureTime frame
Wolf Motor Function Test, ABILHAND, Goal Attainment Scaling.

Secondary

MeasureTime frame
Motricity index, plate tapping task, active range of motion, perceived strength, perceived fatigue.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)